April 2020 DISCLAIMER Cautionary Note Regarding Forward-Looking - - PowerPoint PPT Presentation

CURALEAF INVESTOR’S PRESENTATION April 2020

Cautionary Note Regarding Forward-Looking Statements and Future-Oriented Financial Information This presentation contains “forward-looking information” and “forward-looking statements” within the meaning of the Canadian securities laws and the United States Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management’s current beliefs, expectations or assumptions regarding the future of the business, future plans and strategies, operational results and other future conditions of Curaleaf Holdings,

• Inc. (the “Company”). In addition, the Company may make or approve certain statements in future filings with Canadian securities regulatory authorities, in press releases, or in oral or written presentations by representatives of the Company that are not statements of historical fact

and may also constitute forward-looking statements. All statements, other than statements of historical fact, made by the Company that address activities, events or developments that the Company expects or anticipates will or may occur in the future are forward-looking statements, including, but not limited to, statements preceded by, followed by or that include words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “outlook”, “objective”, “forecasts”, “designed”, “goal”, or the negative of those words or other similar or comparable words and includes, among others, information regarding: ability of the Company to complete the transactions described herein and the anticipated benefits to the Company of the transactions described herein, including the expectations for the effects of such transactions; statements relating to the business and future activities of, and developments related to, the Company after the date of this presentation, including such things as future business strategy, competitive strengths, goals, expansion and growth of the Company’s business, operations and plans; expectations that planned acquisitions will be completed; expectations that licenses applied for will be obtained; potential future legalization of adult-use and/or medical cannabis under U.S. federal law; expectations of market size and growth in the U.S. and the states in which the Company operates; expectations for other economic, business, regulatory and/or competitive factors related to the Company or the cannabis industry generally; and other events or conditions that may occur in the future. Forward-looking statements may relate to future financial conditions, results of operations, plans, objectives, performance or business developments. These statements speak only as of and at the date they are made and are based

• n information currently available and on the then current expectations. Holders of securities of the Company are cautioned that forward-looking statements are not based on historical facts but instead are based on reasonable assumptions and estimates of management of the

Company at the time they were provided or made and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, as applicable, to be materially different from any future results, performance

• r achievements expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: the failure of the Company to complete the transactions described herein; the ability of the Company to successfully integrate the business of

Cura Partners, Inc. (“Select”) and GR Companies, Inc. (“Grassroots”) and their respective corporate cultures; the available funds of the Company and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the cannabis industry; risks associated with economic conditions, risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the cannabis industry; risks related to contracts with third-party service providers; risks related to the enforceability of contracts; reliance on the expertise and judgment of senior management of the Company, and ability to retain such senior management; risks related to proprietary intellectual property and potential infringement by third parties; the concentrated voting control of the Company’s Executive Chairman, Boris Jordan, and the unpredictability caused by the capital structure; risks relating to the management of growth; increasing competition in the industry; risks inherent in an agricultural business; risks relating to energy costs; risks associated to cannabis products manufactured for human consumption including potential product recalls; reliance on key inputs, suppliers and skilled labor; cybersecurity risks; ability and constraints on marketing products; fraudulent activity by employees, contractors and consultants; tax and insurance related risks; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effecting service outside of Canada; risks related to future acquisitions or dispositions; sales by existing shareholders; limited research and data relating to cannabis; risks related to sale of hemp-based CBD products; as well as those risk factors discussed under “Risk Factors” in the Company’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Year Ended December 31, 2019 (“MD&A”) and other documents filed by the Company with Canadian securities regulatory authorities. The purpose of forward-looking statements is to provide the reader with a description of management’s expectations, and such forward-looking statements may not be appropriate for any other purpose. In particular, but without limiting the foregoing, disclosure in this presentation as well as statements regarding the Company’s objectives, plans and goals, including future operating results and economic performance may make reference to or involve forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. A number of factors could cause actual events, performance or results to differ materially from what is projected in the forward-looking statements. You should not place undue reliance on forward-looking statements contained in this presentation. Such forward-looking statements are made as of the date of this presentation. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The Company’s forward-looking statements are expressly qualified in their entirety by this cautionary statement. Cannabis-Related Practices or Activities are Illegal Under U.S. Federal Laws The focus of Curaleaf’s business is the cannabis industry. The concepts of “medical cannabis” and “adult-use cannabis” do not exist under U.S. federal law. The U.S. Federal Controlled Substances Act classifies “marihuana” as a Schedule I drug. Accordingly, cannabis-related practices

• r activities, including without limitation, the manufacture, sale, importation, possession, use or distribution of cannabis and its derivatives are illegal under U.S. federal law and the enforcement of the relevant laws poses a significant risk. These laws and their enforcement are in flux

and vary dramatically from jurisdiction to jurisdiction. The enforcement of these laws and its effect on the Company and its business, employees, directors and shareholders are uncertain, and accordingly, involve considerable risk. Strict compliance with state laws with respect to cannabis will neither absolve the Company of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against the Company. Any such proceedings brought against the Company may adversely affect the Company’s operations and financial performance. See “Risk Factors – Cannabis is a Controlled Substance under the United States Federal Controlled Substances Act” in the MD&A.

DISCLAIMER

2

Cautionary Note to United States Investors The securities of the Company have not been and will not be registered under any United States federal or state securities law and may not be offered and sold in the United States, except that securities may be offered and sold to an investor that is an “accredited investor” as defined in Regulation D of Securities Act of 1933, as amended (the “U.S. Securities Act”), of the United States of America or to a limited number of Qualified Institutional Buyers (as defined in Rule 144A under the U.S. Securities Act. IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY, INCLUDING THE MERITS AND RISKS INVOLVED. THE COMPANY’S SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR BY ANY STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES OR ANY CANADIAN PROVINCIAL SECURITIES REGULATOR PASSED ON THE ACCURACY OR ADEQUACY OF THIS PRESENTATION. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. The Company’s securities will not be and have not been registered under the U.S. Securities Act or the securities laws of any state of the United States, and if sold in the United States will be “restricted securities” within the meaning of Rule 144 under the U.S. Securities Act. The Company’s securities may be resold, pledged or otherwise transferred only pursuant to an effective registration statement under the U.S. Securities Act or pursuant to an applicable exemption from the registration requirements of the U.S. Securities Act. Cautionary Note to European Investors European laws, regulations and their enforcement, particularly those pertaining to anti-money laundering, relating to making and/or holding investments in cannabis-related practices or activities are in flux and vary dramatically from jurisdiction to jurisdiction. The enforcement of these laws – some of which carry criminal liability - and their effect on shareholders are uncertain and involve considerable risk. Accordingly, all potential investors located in Europe (including without limitation, the United Kingdom) should take their own, independent legal advice based on their own circumstances prior to making any investment into the Company (whether directly or indirectly or acting on an agency or principal basis). No Company securities shall or will be admitted to trading on a regulated market situated or operating in the European Economic Area or be advertised, offered, sold, transferred or delivered to the public in the European Economic Area. If any Company securities shall only be advertised, offered, sold, transferred or delivered to persons by making use of the exemption from the obligation to publish a securities prospectus with regard to the type of offer pursuant to Article 3(2) of the Prospectus Directive 2003/71/EG and amendments thereto, including the 2010 Prospectus Directive Amending Directive 2012/73/EU, implemented in the Member State of the European Economic Area that has implemented the Prospectus Directive, including any relevant implementing measure in each Relevant Member State (the “Prospectus Directive”). The representatives of the Company do not intend to target the European Economic Area market with regard to a public offering or an offering other than permitted by Article 3(2) of the Prospectus Directive. Non-IFRS Financial Measures In this presentation, Curaleaf refers to certain non-IFRS financial measures such as Pro Forma Revenue (“PF Revenue”), Managed Revenue, Gross Profit on Cannabis Sales and Adjusted EBITDA (“AEBITDA”). These measures do not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other issuers. Curaleaf defines Managed Revenue as total revenue plus revenue from entities for which the Company has a management contract but does not consolidate the financial results based on IFRS 10 – Consolidated Financial Statements. Curaleaf defines PF Revenue as Managed Revenue plus revenue from operations of pending and closed acquisitions as if such acquisitions occurred on January 1 of the year presented. Pro Forma information for the Select and Grassroots acquisitions is based on information provided by the target companies. Curaleaf defines Gross Profit on Cannabis Sales as retail and wholesale revenues less cost of goods sold. AEBITDA is defined by Curaleaf as earnings before interest, taxes, depreciation and amortization less share-based compensation expense and one-time charges related to acquisition and financing related costs. Curaleaf considers these measures to be an important indicator of the financial strength and performance of its business. Currency All financial information is in U.S. dollars, unless otherwise indicated. Third Party Information Certain of the forward-looking statements and other information contained herein concerning the cannabis industry, its medical, adult-use and hemp-based CBD markets, and the general expectations of the Company concerning the industry and the Company’s business and

• perations are based on estimates prepared by the Company using data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be
• reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise and the Company has not independently verified any of the data from third-party sources referred to in this presentation,
• r analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. To the extent such information obtained from third party sources, there is a risk that the assumptions made and

conclusions drawn by the Company based on such representations are not accurate, and the cannabis industry involves risks and uncertainties that are subject to change based on various factors. The Company does not make any representation or warranty, express or implied as to, and no reliance should be placed on, the fairness, completeness, correctness or accuracy of such information.

DISCLAIMER

3

UPDATE ON CURALEAF’S RESPONSE TO COVID-19

• We have received an Essential Services Designation in key markets,

allowing the company to continue to meet the needs of its customers

• We are hiring a variety of positions and working closely with local
• rganizations to provide job opportunities to those who are out of work

due to the crisis

• We have dedicated the first operating hour of each day exclusively for

patients and customers 60 years of age or older

• We are enforcing social distancing, increasing sanitation and hygiene

measures, using technology to minimize contact, and increasing safety by working to employ curbside delivery, mobile pre-ordering, express pickup and a new waitlist ordering app

• The WaitlistMe app allows our staff to add customers to a

digital waiting list, so they can wait in their cars instead of standing in a line outside the dispensary(1)

• For more information regarding updated state-by-state situations, please

visit: https://curaleaf.com/coronavirus-updates/

OUR RESPONSE TO COVID-19

(1) WaitlistMe is currently available in Arizona, Florida, Maine, Maryland , Massachusetts,, New Jersey, and New York, and we will be adding more states.

COMPANY OVERVIEW

• Executed a non-dilutive $300 million debt raise in

January of 2020, raising net proceeds of $185.7 million(1)

• This provides Curaleaf with one of the strongest

balance sheets in the sector, with ~$228 million of cash on hand at 12/31/19, pro-forma for the debt raise

• Continued support from key shareholders:
• As a group, committed to providing $100 million in

additional capital if needed for opportunistic acquisitions

• Three consecutive quarters of positive AEBITDA,

capping fiscal year 2019 with $26 million of AEBITDA

• Ample cash on hand to fund our current business for

future growth

• Several states continue to generate operating cash

flow paving the way for significant organic cash flow

ONE OF THE MOST WELL CAPITALIZED AND FINANCIALLY STABLE U.S. CANNABIS COMPANIES

7

(1) Net proceeds are after the retirement of prior senior-debt obligations and other fees associated with the debt raise.

hbo December - acquired processing license in MD January - awarded processing license in OH January - won medical retail license in UT January - closed $300 million senior term loan facility January - opened adult-use dispensary in Cape Cod, MA February - awarded clinical registrant license in PA February - closed Select acquisition February - acquisition of vertical operator with largescale operational greenhouse in CA May - acquired option to purchase cultivation and processing licenses in OH May - acquired operating dispensary in AZ June - acquired two vertical licenses in AZ July - announced acquisition of Grassroots(1),(2) August - awarded processing license in CA October - completed RTO and $400M equity financing November - acquired

• perating dispensary in AZ

December - dispensary license awarded in MD December – acquired 1 of 4 licensed cultivators and processors in CT December - acquired 1 of 13 vertically integrated licenses in FL June - acquired OR-based manufacturer, Groen August - acquired licensed cultivator in NV October - acquired dispensary in Las Vegas, NV January - completed acquisition of Acres in NV

2019 2019 2020 2020

Company established as PalliaTech, Inc. a medical device company

2010 2010 2015 2015 2016 2016 2017 2017 2018 2018

October - first dispensary sales in NJ Q1 - entered in partnership agreements in MA and ME May - awarded 1 of 10 vertically integrated licenses in NY April - acquired vertical

• peration with 4 stores in AZ

January - provided convertible debt financing and secured option to purchase cultivation, processing, and dispensary licenses in MD

PIONEERING CANNABIS SINCE 2010: COMPANY MILESTONES

LICENSES APPLIED FOR AND WON

NJ MD NY CA OH UT PA LICENSES OBTAINED THROUGH ACQUISITIONS

ME

MA CT FL OR NV AZ CO

#1 #4 #7 #11 #12 #13 #14 #2 #3 #5 #6 #8 #9 #10 #15

(1) Pending regulatory approval. Refer to Company filings on SEDAR for complete deal terms and associated risks and uncertainties. (2) Refer to Slide 10 for details on the Grassroots acquisition.

8

• One of the most successful acquirors of cannabis assets
• Our focus on return on invested capital brings discipline to acquisitions
• Since our public offering in October 2018 through the end of 2019, we have

successfully closed on and integrated 11 businesses, including Select, which collectively represents 16 dispensaries, 6 cultivation sites, and 15 processing sites

• In calendar 2019 alone, we deployed over $96 million of capital into the

maintenance and expansion of our operations

• March 2020, we announced the acquisition of BlueKudu in Colorado
• One of Colorado's oldest and most experienced edibles manufacturers, known for

utilizing high-quality ingredients sourced from Rainforest Alliance Fair Trade Certified Farms

• April 2020, we closed the acquisition of three Arrow Alternative Care (AAC)

dispensaries in Connecticut

• The dispensaries are situated in key metro areas and enable Curaleaf to be vertically

integrated in the state

PRUDENT ACQUISITIVE GROWTH

2019 - YTD 2020 Acquisitions (Licences)

State

Entity Disp. Cult. Proc.

MA Curaleaf MA 4 1 1 AZ Midtown Roots 1 MD Elevate Takoma 1 MD HMS 2 1 1 CA Eureka 3 1 1 NV Acres 2 1 2 OH OGT 1 1 AZ Emerald Gilbert 1 AZ Phytotherapeutics 1 AZ Glendale Greenhouse 1 1 1 MSO Select 8 MSO Grassroots(1) 50+ 6 8 CO BlueKudu(1) 1 CT Arrow Alternative Care 3 Total 14 ~ 70 12 24

9

(1) Pending regulatory approval. Refer to Company filings on SEDAR for complete deal terms and associated risks and uncertainties.

GRASSROOTS –

PENDING ACRETIVE TRANSACTION

C O N S I D E R AT I O N :

• 108.8 million SVS

~17% of PF ownership

• $75 million cash

G O V E R N A N C E :

• Management continuity
• One board seat

E X P E C T E D C LO S I N G :

• 2020

C LO S I N G H U R D L E S :

• Completed HSR
• Awaiting various state regulatory

approvals

• sq. ft of cultivation

capacity patients served and growing active wholesale dispensary accounts retail locations in operation states with regulated sales addressable population processing facilities in operation cultivation facilities in operation

2,260,000+ 170,000+ 80+ 1,150+ 196,600,000+ 23 20+ 30+

CLEAR INDUSTRY LEADER (1)

11

(1) Pro-forma for Grassroots transaction. Certain entities are subject to option agreements, service agreements, or similar contractual relationships which may require state or local approval and licensing prior to close.

2,260,000+ 170,000+ 0+ 1,150+ 196,600,000+ 23 20+ 30+

CONSIDERABLE MARKET GROWTH

(1) Source: Arcview Market Research, State of Legal Cannabis Markets 7th Edition. (2) Source: Canaccord’s September 2019 U.S. Cannabis and Multi-State Operators report. (3) Source: Marijuana Policy Project; MPP.org as of September 2019. (4) Source: IQVIA Institute for Human Data Science, Global Use of Medicines, January 2019.

$16.0B in 2020 33 STATES 3M+

PATIENTS

GROWTH DRIVERS

• While the U.S. legal cannabis industry is projected to total

$16.0B(1) in 2020, total cannabis demand in the U.S. is estimated to total $75B-$100B(2), including markets serviced by the illicit market

• Today, 33 states, as well as the District of Columbia, Guam

and Puerto Rico, have legalized medical cannabis

• 11 of the 33 states and the District of Columbia have

legalized cannabis for adult-use

• Poised for change in AZ, CT, NJ, and NY
• Nationally, more than 3 million patients have

registered with state medical cannabis programs

• Over 220 million Americans live in states that permit

the use of medical cannabis, 93 million of which are permitted for adult-use(3)

• Expansion of regulated markets and conversion of illicit

markets

• Growth of consumption per capita as new product forms,

such as edibles and vapes, lead to proliferation of use

$9.9 $12.8 $16.0 $19.2 $23.1 $26.8 $30.1 $0.0 $5.0 $10.0 $15.0 $20.0 $25.0 $30.0 $35.0 2018 2019 2020 2021 2022 2023 2024

$ I N B I L L I O N S

L E G A L U . S . C A N N A B I S M A R K E T ( 1 ) A D D R E S S A B L E M A R K E T, U . S .

Prescription Drugs, 2018 $485B(4) Tota

• tal U.

U.S. Cannabis Ma Market (legal+ illicit) $75B-$100B(2) Le Legal U. U.S. Cannabis s Ma Market, 2018 $10B(1)

12

CURALEAF SELECT

Largest footprint of branded retail stores in the U.S.(1) Most recognized lifestyle brand

• n the West Coast

Widely recognized wellness brand on the East Coast Diversification of Curaleaf revenue mix to include wholesale capacity in key adult- use states Supply chain control from seed to sale, with ongoing investment budgeted for cultivation and processing assets Value of strong brand in current markets unlocked through national expansion Capital market access and prudent stewardship of financial resources Compelling synergies with Curaleaf supply chain Unparalleled management pedigree Leadership with strengths in product innovation, sales and marketing, and retail channel access

+

THE CURALEAF + SELECT UNION

(1) Based on publicly available data.

13

THE CURALEAF + SELECT UNION

CA CA OR OR NV NV AZ AZ

OREGON Vertically integrated 1 dispensary license ARIZONA Vertically integrated 8 dispensary licenses CALIFORNIA Vertically integrated 3 dispensary licenses NEVADA Vertically integrated 3 dispensary licenses

CO CO OH OH

FLORIDA Vertically integrated Top 3 market share(2) NEW YORK Vertically integrated 1 of 10 licenses NEW JERSEY Vertically integrated 35%+ market share(1) 1 of 12 licenses MARYLAND Vertically integrated 4 dispensary licenses MAINE Vertically integrated 2 of 8 licenses OHIO 1 of 17 large grow licenses MASSACHUSETTS Vertically integrated 100K sq. ft. cultivation PENNSYLVANIA Obtained clinical registrant license CONNECTICUT Vertically integrated 1 of 4 producers

ME ME NY NY PA PA NJ NJ MD MD CT CT MA MA FL FL

MICHIGAN Select wholesale presence COLORADO 1 processing license (3) UTAH 1 dispensary and 1 processing license

MI MI UT UT

(1) Source: New Jersey Department of Health Division of Medical Marijuana Biennial Report April 2019. (2) Source: Florida Department of Health Office of Medical Marijuana Use Weekly Updates, March 2020. (3) Pro-forma for BlueKudu transaction.

KY KY

KENTUCKY CBD processing capabilities 14

GRASSROOTS U.S. EXPANSION AND MARKET DIVERSIFICATION

(1)

NV NV PA PA VT VT AR AR IL IL OH OH OK OK NORTH DAKOTA Vertically integrated 1 of 2 cultivation licenses PENNSYLVANIA Vertically integrated Top 3 retail market share ARKANSAS 1 dispensary license OKLAHOMA 7 dispensary licenses NEVADA 7 dispensary licenses OHIO Vertically integrated 2 dispensary licenses

`

MI MI MICHIGAN 4 dispensary licenses MISSOURI 5 dispensary licenses 3 processing licenses ILLINOIS Vertically integrated Top 3 retail market share MARYLAND

Vertically integrated 2 dispensary licenses

VERMONT Vertically integrated Largest license holder in state AZ AZ ND ND

MO MO

• Strong leadership team with
• utstanding track record in securing

licenses through organic means

• Attractive vertically integrated

asset mix with $120 million invested since inception

• Strong retail presence in key limited-

license states

• Curaleaf gains entry to highly

populous, vertically integrated markets in the Midwest

(1) Certain entities are subject to option agreements, service agreements, or similar contractual relationships which require state or local approval and licensing prior to close.

O V E R L A P P I N G P R E S E N C E N E W C U R A L E A F P R E S E N C E

ARIZONA 1 dispensary license CONNECTICUT Vertically integrated 1 of 4 producers

15

COMBINED: STRONG PRESENCE NATIONWIDE WITH SCALE & DIVERSITY

ME ME NY NY PA PA OH OH FL FL

OR OR CA CA NV NV AZ AZ

MI MI AR AR IL IL VT VT

OREGON Vertically integrated Leading market share 37K sq. ft. cultivation

ARIZONA

Vertically integrated Leading market share 9 dispensary licenses

NEW YORK

Vertically integrated

1 of 10 licenses NEW JERSEY Vertically integrated 35%+ market share 1 of 12 licenses

MASSACHUSETTS

Vertically integrated 100K sq. ft. cultivation

FLORIDA

Vertically integrated Top 3 market share 28 operational dispensaries

C O M B I N E D C O M P A N Y A N T I C I P A T E D T O H A V E A S T R O N G P R E S E N C E I N 2 3 S T A T E S I N 2 0 2 0 ( 1 ) , ( 2 )

OK OK ND ND MICHIGAN

Vertically integrated 4 dispensary licenses

PENNSYLVANIA

Vertically integrated Top 3 retail market share NEVADA Vertically integrated Leading market share 10 dispensary licenses 279K sq. ft. cultivation

MAINE

Vertically integrated 2 of 8 licenses

VERMONT

Vertically integrated 2 of 5 licenses

MARYLAND

Vertically integrated Leading retail market share

ARKANSAS

1 dispensary license

OKLAHOMA

7 dispensary licenses

OHIO

Vertically integrated 2 dispensary licenses

ILLINOIS

Vertically integrated Top 3 retail market share

CONNECTICUT Vertically integrated

4 of 18 dispensary licenses 1 of 4 producers

CALIFORNIA

Vertically integrated Leading market share 110K sq. ft. cultivation 3 dispensary licenses

NORTH DAKOTA

Vertically integrated 1 of 2 cultivation licenses

NEW STATES

(1) Pro-forma for Grassroots transaction. Certain entities are subject to option agreements, service agreements, or similar contractual relationships which may require state or local approval and licensing prior to close. (2) Accounting for THC markets. (3) Combines Select assets; acquisition was closed on February 1, 2020. (4) Pro-forma for BlueKudu transaction.

(3)

UT UT

UTAH

1 dispensary license 1 processing license

CO CO

COLORADO

1 processing license(4)

KY KY MO MO MISSOURI

5 dispensary licenses

COMBINED: STRONG PRESCENCE NATIONWIDE WITH SCALE & DIVERSITY

KENTUCKY

CBD processing capabilities 16

FOCUS ON CORE, STABLE, MEDICAL-USE REVENUE GENERATION EXPANSION INTO ADULT-USE MARKETS BRAND BUILDING THROUGH COAST -TO- COAST ROLLOUT OF WELLNESS AND LIFESTYLE PRODUCTS EXPANDED RETAIL CHANNEL OWNERSHIP AND WHOLESALE ACCESS INCREASED VERTICAL INTEGRATION THROUGH INVESTMENT IN CULTIVATION AND PROCESSING

STRATEGY SUMMARY

17

0+ 1,150+ 20+ 30+

CORE, STABLE MEDICAL REVENUE

C U R A L E A F ’ S M E D I C A L C A N N A B I S B U S I N E S S F E AT U R E S S T R O N G , P R E D I C TA B L E R E V E N U E S

M E D I C A L R E V E N U E S C O N T I N U E T O P R O V I D E A S TA B L E B A S E E V E N A F T E R A S TAT E B E G I N S A D U LT - U S E S A L E S

$- $20.00 $40.00 $60.00 $80.00 $100.00 $120.00 $140.00 $160.00 Jan-14 May-14 Sep-14 Jan-15 May-15 Sep-15 Jan-16 May-16 Sep-16 Jan-17 May-17 Sep-17 Jan-18 May-18 Sep-18 Jan-19 May-19 Sep-19 Jan-20

Colorado Cannabis Sales(2)

Medical Adult-Use $- $10.00 $20.00 $30.00 $40.00 $50.00 $60.00

Nevada Cannabis Sales

Medical Adult-Use

Active Patients Visits/Month GrossRevenue Spend/Visit

90,039 2.34 $83.41 $17.6M

x x

=

D E C 2 0 1 9 D E C 2 0 1 8

44,398 2.16 $85.90 $3.3M

x x

=

P a t i e n t M e t r i c s ( M e d i c a l O n l y ) ( 1 )

(1) Includes states with medical cannabis programs in which Curaleaf operates. (2) Source: BDS Analytics January 2020.

18

2,260,000+ 170,000+ 0+ 1,150+ 196,600,000+ 23 20+ 30+

RETAIL CHANNEL & WHOLESALE ACCESS

CURALEAF & GRASSROOTS RETAIL CURALEAF & SELECT WHOLESALE

130+

S T O R E S ( 1 )

80+ 80+

S T O R E S ( 1 )

D I S T R I B U T E T O

1 ,0 0 0 + STORES

P L U G + P L A Y G R O W T H B O O S T

(1) Pro-forma for Grassroots transaction. Certain entities are subject to option agreements, service agreements, or similar contractual relationships which may require state or local approval and licensing prior to close.

19

1 7 1 3 8 2 5 7 5 7 3 5 2 3 ( 1 ) 1 3 9 D I S P E N S A R Y L I C E N S E S S TAT E S A C T I V E L O C AT I O N S 9 2 W H O L E S A L E PA R T N E R S C U R R E N T C U LT I VAT I O N 1 5 0 1 1 9 , 0 0 0 S Q U A R E F E E T 1 , 0 0 0 1 . 3 M I L L I O N S Q U A R E F E E T 1 . 4 M I L L I O N S Q UA R E F E E T E X PA N D A B L E T O 2 . 3 M I L L I O N S Q . F T. 1 , 1 5 0 ~ 1 6 5 M ~ 3 2 M ( 3 ) ~ 1 9 7 M T OTA L P O P U L AT I O N ( 2 ) $ 1 2 . 9 B $ 1 . 1 B ( 3 ) $ 1 4 . 0 B R E P R E S E N T S 8 7 % O F T OTA L U . S . R E TA I L M A R K E T 2 0 2 0 R E TA I L C A N N A B I S M A R K E T ( 4 )

(1) Overlapping state presence in AZ, CT, MD, NV, MI, PA, and OH. (2) Source: US Census Bureau Statistics as of July 1, 2018 (published December 19, 2018). (3) Excludes overlapping states: AZ, CT, MD, NV, MI, PA, and OH. (4) Source: Arcview Market Research, State of Legal Cannabis Markets 7th Edition.

SUMMING THE PARTS

20

2,260,000+ 170,000+ 0+ 1,150+ 196,600,000+ 23 20+ 30+

BRANDS SPANNING MEDICAL & ADULT-USE SEGMENTS

WELLNESS LIFESTYLE

21

2,260,000+ 170,000+ 0+ 1,150+ 196,600,000+ 23 20+ 30+

CONTINUED INVESTMENT IN VERTICAL INTEGRATION UNLOCKS VALUE

VERTICAL MODEL: CURALEAF & GRASSROOTS WHOLESALE MODEL: CURALEAF & SELECT

=

INTEGRATED MODEL

O W N E D R E TA I L P R O C E S S C U LT I V AT I O N DISTRIBUTION NETWORK P R O C E S S P U R C H A S E O W N E D R E TA I L P R O C E S S C U LT I V AT I O N DISTRIBUTION NETWORK P R O C E S S P U R C H A S E

+ =

P R O C E S S C U LT I VAT I O N D I S T R I B U T I O N N E T W O R K O W N E D R E TA I L

Supercharging Curaleaf’s advantages of vertical integration with extensive distribution network and sales team capability

22

2,260,000+ 170,000+ 0+ 1,150+ 196,600,000+ 23 20+ 30+

MANAGEMENT EXPERIENCE: CURALEAF & SELECT

Joseph Lusardi CEO Boris Jordan Executive Chairman

• f the Board

Neil Davidson COO Cameron Forni President of Select Jason White CMO Michael Carlotti CFO Joseph Bayern President Over 9 years developing and

• perating

medicinal cannabis companies Over 20 years of experience in finance and private equity Investor in cannabis companies with extensive capital markets and operating experience Founded Sputnik Group in 1999 Accomplished finance professional with over 20 years of experience including leading publicly-traded and private equity owned businesses Founder of Select, one

• f the best-selling

cannabis brands on the West Coast Honored as one of the 100 Most Influential People in Cannabis by High Times Magazine, NCAA hockey champion Over 20 years of experience in business management and marketing, as well as building and leading global consumer brands Over 25 years of experience in capital markets, M&A, investment banking and corporate finance; Previously the CFO of a Nevada-based cannabis company and Treasurer of MGM Resorts International Over 20 years of executive leadership experience in consumer-packaged goods companies Previous President of INDUS Holdings, a vertically integrated cannabis company

Note: logos representative of entire management senior executive suite, not just those shown above.

23

2,260,000+ 170,000+ 0+ 1,150+ 196,600,000+ 23 20+ 30+

MANAGEMENT EXPERIENCE: GRASSROOTS (1)

Co-founded Grassroots Cannabis in 2014 Extensive entrepreneurial and corporate governance experience, previously counseled private equity sponsors and portfolio companies on M&A as an attorney at Kirkland & Ellis LLP Steven Weisman Chief Strategy Officer

Andy Cohen Partner & Market President, Maryland

25+ years of experience in leadership, brand building and financial management Previously founded and led specialty retailer Water Water Everywhere Josh Joseph Principal & Director, Real Estate 25+ years of real estate experience; closed over $1.5 billion in transactions across 40 states A Founder and Principal

• f Frontline Real Estate

Partners, a full-service commercial real estate firm

Mitch Kahn Founder & CEO Matt Darin COO & CFO

Co-founded Grassroots Cannabis in 2014 Over 20 years of chief executive experience in commercial real estate Co-founded Grassroots Cannabis in 2014 More than 15 years as an entrepreneur and executive in the cannabis and commercial real estate industries 15+ years of experience in the agency business Previously served as VP, Global Brand Design at Kimberly-Clark; EVP at Starcom Mediavest Group and Leo Burnett / Arc; spent 7 years at P&G Lisa Hurwitz Chief Marketing and Innovation Officer

Note: logos representative of entire management senior executive suite, not just those shown above.

24

(1) Subject to customary closing conditions including regulatory approval.

WHY CURALEAF? WHY NOW?

(1) Pro-forma for Grassroots transaction. (2) By population for states with active medical and/or adult-use programs. (3) Total amount of locked-up shares equals 302 million.

WELL-CAPITALIZED

Three consecutive quarters of positive AEBITDA coupled with one of the strongest balance sheets in the sector; ample cash to fund business for future growth

SCALE

Through acquisitive and organic growth, we have established the largest footprint of branded retail stores in the U.S., having a combined 80+ operational dispensaries, 30+ processing, and 20+ cultivation facilities, with the ability to grow to 130+ dispensaries, 30+ processing, and 20+ cultivation facilities(1)

NATIONAL PRESENCE

Coast-to-coast footprint in densely populated states with proven ability to win licenses in competitive state-run processes, presence in 11 of the 12 largest markets(2)

PRODUCT CATEGORY LEADERS

Most trusted and reliable brands producing consistent and high-quality products with leading market share in several key states

COMMITTED SHAREHOLDER BASE

Key shareholders, who represent 71% of locked-up shares(3) and have not sold a single share, are prepared to commit $100 million in additional capital

MANAGEMENT TEAM

Aligned management teams with similar core philosophies and strong track records of execution; over 125 years of combined management and leadership experience in a diverse range of industries

UPSIDE

Uniquely positioned to capture market opportunities through our strong financial position, prudent use of capital, deal synergies, and significant anticipated revenue upside from build-out of additional facilities

APPENDIX

SELECTED HISTORICAL FINANCIAL DATA: TRACK RECORD OF GROWTH (1),(2)

(1) Managed Revenue, Gross Profit on Cannabis Sales and AEBITDA are certain non-IFRS financial measures. A reconciliation of non-IFRS financial measures is provided on Slide 27. (2) $42.3 million represents cash at the end of fiscal year 2019, does not reflect impact of the January 2020 debt raise.

($ in millions)

Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 FY 2017 FY 2018 FY 2019 Total Revenue 21.4 $ 32.0 $ 35.3 $ 48.5 $ 61.8 $ 75.5 $ 19.3 $ 77.1 $ 221.0 $ Managed Revenue 24.3 34.9 40.7 55.1 73.2 81.7 28.4 87.8 250.6 Gross Profit on Cannabis Sales 9.1 11.8 10.6 15.3 23.6 22.0 1.5 26.4 71.5 AEBITDA (2.8) (1.4) (3.7) 3.4 10.4 13.8 3.8 (10.4) 25.9 Cash 48.1 $ 266.6 $ 172.6 $ 107.3 $ 91.2 $ 42.3 $ 21.0 $ 266.6 $ 42.3 $ PP&E 48.9 67.0 82.5 103.8 109.9 129.8 23.5 67.0 129.8 Total Assets 253.1 569.8 601.2 655.1 713.2 736.9 151.6 569.8 736.9 Total Liabilities 200.0 134.2 174.7 223.8 287.9 333.5 46.8 134.2 333.5 Shareholder's Equity 53.1 435.6 426.5 431.2 425.3 403.4 151.6 435.6 403.4

27

NON-IFRS FINANCIAL MEASURES RECONCILIATION

($ in millions)

Managed Revenue Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 FY 2017 FY 2018 FY 2019 Total Revenue 21.4 $ 32.0 $ 35.3 $ 48.5 $ 61.8 $ 75.5 $ 19.3 $ 77.1 $ 221.0 $ Revenue from Managed Entities, net of MSA Fees 3.0 2.9 5.4 6.6 11.4 6.2 9.0 10.7 29.6 Managed Revenue 24.3 $ 34.9 $ 40.7 $ 55.1 $ 73.2 $ 81.7 $ 28.4 $ 87.8 $ 250.6 $ Gross Profit on Cannabis Sales Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 FY 2017 FY 2018 FY 2019 Retail and Wholesale Revenue 16.6 $ 23.7 $ 27.8 $ 37.7 $ 50.7 $ 57.7 $ 9.4 $ 57.5 $ 173.9 $ Costs of Goods Sold 7.5 12.0 17.1 22.5 27.1 35.7 7.8 31.2 102.4 Gross Profit on Cannabis Sales 9.1 $ 11.8 $ 10.6 $ 15.3 $ 23.6 $ 22.0 $ 1.5 $ 26.4 $ 71.5 $ AEBITDA Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 FY 2017 FY 2018 FY 2019 Net Loss (35.6) $ (16.5) $ (10.8) $ (24.4) $ (7.4) $ (27.2) $ (5.0) $ (61.9) $ (69.9) $ Interest Expense, Net 1.0 2.7 2.6 2.9 4.2 5.1 (1.4) 2.5 14.8 Income Tax Recovery (Expense) 2.7 1.9 (1.4) 8.2 5.3 12.0 1.1 5.6 24.1 Deprecation and Amortization 1.3 3.8 4.9 7.2 10.4 12.7 3.2 8.7 37.2 Share-Based Compensation (0.0) 1.1 1.8 4.5 4.7 5.7 2.5 2.2 16.6 Other (Income) Expense 25.1 (0.0) 0.0 1.1 (0.6) 2.8 (1.2) 25.1 3.3 Change in Fair Value of Biological Assets 0.2 1.4 (2.2) (1.4) (13.8) (5.5) 4.1 (0.4) (23.0) One Time Charges 2.6 4.2 1.5 5.3 7.8 8.3 0.4 7.8 22.8 AEBITDA (2.8) $ (1.4) $ (3.7) $ 3.4 $ 10.4 $ 13.8 $ 3.8 $ (10.4) $ 25.9 $

28